Empowered Funds LLC Buys Shares of 23,220 Becton, Dickinson and Company $BDX

Empowered Funds LLC purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 23,220 shares of the medical instruments supplier’s stock, valued at approximately $3,514,000.

A number of other institutional investors have also modified their holdings of the company. Imprint Wealth LLC purchased a new stake in Becton, Dickinson and Company in the 3rd quarter worth approximately $25,000. SHP Wealth Management purchased a new position in shares of Becton, Dickinson and Company during the 4th quarter worth $26,000. Meeder Asset Management Inc. boosted its holdings in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares during the last quarter. Main Street Group LTD acquired a new stake in shares of Becton, Dickinson and Company during the first quarter worth $29,000. Finally, Bell Investment Advisors Inc purchased a new stake in shares of Becton, Dickinson and Company in the second quarter valued at $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 9,105 shares of company stock worth $1,590,208. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Price Performance

BDX stock opened at $187.23 on Wednesday. The stock has a 50-day moving average price of $167.95 and a two-hundred day moving average price of $160.37. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $193.07. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The company has a market cap of $51.59 billion, a PE ratio of 56.39, a price-to-earnings-growth ratio of 13.26 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the business posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. UBS Group started coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price on the stock. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. The Goldman Sachs Group cut their price objective on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. Jefferies Financial Group reissued a “buy” rating and issued a $210.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Finally, Barclays upped their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $187.67.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.